Subscribe

Spotlight -

This Year In Medicine 2025

Henrik Watz, MD, PhD

Henrik Watz, MD, PhD | Credit: ADVENT

Professor, University of Kiel, Kiel, Germany | Medical Director, Velocity Clinical Research Grosshansdorf, Grosshansdorf, Germany

Articles by Henrik Watz, MD, PhD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD

ByHenrik Watz, MD, PhD

October 20th 2026

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Latest Updated Articles

Trending on HCPLive

FDA Approves Bepirovirsen for Chronic Hepatitis B

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know